Jefferies & Co
-
Jefferis Remains Positive on Shares of Ardea Biosciences (RDEA) Following 28-Week Extension Data For Lesinurad-Allopurinol Combination
-
Jefferies Raises Price Target on Ardea Biosciences (RDEA), Maintains Buy Rating
-
Jefferies Raises Ardea Biosciences's (RDEA) Price Target to $30, Maintains Rating at Buy
-
Ardea Biosciences (RDEA) Completes 4.03M Common Offering; Net Proceeds of $77.1M
-
Ardea Biosciences (RDEA) to Offer 3.5M in Common Stock
-
Jefferies & Co Initiates/Resumes Coverage on Pharma/Biotechnology Stocks
